Replies to post #73211 on Biotech Values

[DewDiligence]

Re: IDIX’s HCV protease inhibitors

Has IDIX added any color to the differences between IDX136 and IDX316, the protease inhibitors? I know they only plan to advance one into trials.

IDX136 will probably get the first shot because it has a longer half-life. Whichever compound is not selected will become the lead backup.

has IDIX commented on any specific potential advantages that either compound may have compared to Telaprevir, Boceprevir, or any of the other PIs under development?

In the HCV replicon, IDX136/316 have antiviral activity at lower doses than Telaprevir and Boceprevir and they have less off-target activity against host proteases.